Skip to main content

Table 2 Gadolinium based contrast agents—elimination pathway, last reported total number of administrations, occurrences of NSF and volume of excess chelate quantity [11]

From: Revisiting the risks of MRI with Gadolinium based contrast agents—review of literature and guidelines

Gadolinium based contrast agents Elimination pathway Number of reports No. administrations (millions) Excess chelate in preparation
Unconfounded Confounded
Omniscan®
(Gadodiamide)
Kidney 438 90 47 25 mmol/L
Optimark®
(Gadoversetamide)
Kidney 7 11 0.8 35 mmol/L
Magnevist®
(Gadopentetate dimeglumine)
Kidney 135 276 95 135 mmol/L
Multihance®
(Gadobenate dimeglumine)
97 % Kidney
3 % Bile
0 8 6 1 mmol/L
Primovist®
(Gadoxetic acid disodium salt)
50 % Bile
50 % Kidney
0 0 0.15 (Not known)
Vasovist®
(Gadofosveset trisodium)
91 % Kidney
9 % Bile
0 0 0.05 (Not known)
Prohance®
(Gadoteridol)
Kidney 1* 2 2.6 1 mmol/L
Gadovist®
(Gadobutrol)
Kidney 1 13 12.3 2 mmo/L
Dotarem®
(Gadoteric acid)
Kidney 1** 11 22.4 0
  1. *Case published on 5 October 2009
  2. **9 years prior to Dotarem administration, the patient had received an unknown GBCA. Case is still under investigation